Form 6-K GSK plc For: Jul 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
GSK halts camlipixant development for chronic cough after mixed results
July 17, 2026 6:55 AM EDTGSK plc (NYSE: GSK) announced it will not advance camlipixant, a P2X3 receptor antagonist, for the treatment of refractory chronic cough (RCC) after mixed results from two phase III clinical trials.
The CALM-1 trial met its primary endpoint, showing statistically significant reductions in 24-hour cough... More
